Theralase to Present at Alpha North Investor Conference

Toronto, Ontario – January 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that Roger Dumoulin-White, President and CEO of Theralase will present at the 2nd Annual AlphaNorth Capital Conference to be held at the Atlantis Resort on Paradise Island, Bahamas from January 16th to 18th, 2015.

The 2nd Annual AlphaNorth Capital Conference in the Bahamas will feature some of the best small cap innovators in the technology, biotech, healthcare and special situations spaces and connect them with the top institutions and specialist brokers in North America through a full day series of one-on-one meetings between issuers and finance.

Roger Dumoulin-White, President and CEO of Theralase stated that, “In 2015, one of Theralase’s key objectives is to introduce the Theralase story to new Canadian, US and international investors to allow them the opportunity to hear firsthand of our successes to date and the compelling reasons why investment in Theralase could prove advantageous, as we execute on our strategic objectives. The 2nd Annual AlphaNorth Capital Conference allows us the opportunity to introduce Theralase to numerous institutions that are interested in high growth, healthcare technology companies, such as Theralase”.


About Theralase Technologies Inc.

Founded in 1994, Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Pink®) designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1,200 systems to licensed healthcare practitioners, including: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been so successful in healing nerve, muscle and joint conditions in clinical practice that Theralase’s scientists and clinicians have now turned their attention to investigating the application of its lasers in the destruction of cancer, using specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to the cancer cells and when light activated, destroy them.

Additional information is available at and .

 This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.


For More Information:

Roger Dumoulin-White
President & CEO, Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225